Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02559895 · ClinicalTrials.gov registry record · Phase 3
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
A Phase 3 study of Migraine Disorders, sponsored by Alder Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 898
- Enrollment target
- 20
- Study locations
NCT02559895: Completed Phase 3 study of Migraine Disorders, sponsored by Alder Biopharmaceuticals.
NCT02559895 is a Phase 3 study of Migraine Disorders that has completed, run by Alder Biopharmaceuticals. The registered enrollment target is 898 participants, above the 272-participant average among 21 other Migraine Disorders trials with a reported enrollment target (230% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02559895, a Phase 3 study of Migraine Disorders, has completed, sponsored by Alder Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 898 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
Primary Outcome
Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 1-12
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALD403
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Fresno
- Research Site - Fullerton
- Research Site - Long Beach
- Research Site - Montclair
- Research Site - Oceanside
- Research Site - Redlands
- Research Site - San Diego
- Research Site - San Diego
- Research Site - Santa Monica
- Research Site - Sherman Oaks
Arizona
- Research Site - Phoenix
- Research Site - Tucson
Colorado
- Research Site - Colorado Springs
- Research Site - Fort Collins
Connecticut
- Research Site - Stamford
- Research Site - Waterbury
Alabama
- Research Site - Birmingham
Arkansas
- Research Site - Little Rock
Florida
- Research Site - Bradenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 898 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-12 |
| Phase | Phase 3 |
What the finished NCT02559895 record still lists
NCT02559895 is an interventional study that assigns participants to a tested intervention. The registered 898 participants enrollment target is mid-sized for trials with a published cap, above the 272-participant average among 21 other Migraine Disorders trials with a reported enrollment target (230% higher).
The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02559895 names 20 study sites across 7 states, led by California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT02559895 about?
NCT02559895 is a clinical study titled "A Multicenter Assessment of ALD403 in Frequent Episodic Migraine". The purpose of this study is to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.
What is the current status of trial NCT02559895?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 898 participants. The study started on 2015-09. Estimated completion is 2017-12.
What conditions does trial NCT02559895 study?
This clinical trial studies the following conditions: Migraine Disorders.
What interventions are being tested in trial NCT02559895?
The interventions under investigation include: Placebo (DRUG), ALD403 (DRUG).
Who is sponsoring clinical trial NCT02559895?
This trial is sponsored by Alder Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02559895 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02559895's enrollment target sits among peer trials
898 2nd of 21 the highest of 21 other Migraine Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 3 Study of MAP0004 in Adult Migraineurs
COMPLETED · Phase 3
-
Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents
COMPLETED · Phase 3
-
Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
COMPLETED · Phase 3
-
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea
COMPLETED · Phase 3
-
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 3
-
Migraine Manager (R01)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia